North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Results
Looking for
Spironolactone
found
15 matches
Open monograph to display formulary status
BNF Category
Spironolactone
Cardiovascular system - Aldosterone antagonists - 02.02.03
Spironolactone
Endocrine system - Gender dysphoria - 06.04.04
Spironolactone
Skin - Oral preparations for acne - 13.06.02
Spironolactone
and chlorothiazide capsules
Cardiovascular system - Potassium-sparing diuretics with other diuretics - 02.02.04
Eplerenone
Cardiovascular system - Aldosterone antagonists - 02.02.03
Links
Link to Drug Section
Link to document
MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.02.03)
MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.05.05)
MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.05.05.01)
MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.05.05.02)
MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.05.05.03)
MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.02.03)
MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.05.05.03)
MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.05.05.02)
MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.05.05)
MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.05.05.01)
